Literature DB >> 10963301

Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats.

H Furuichi1, R Fukuyama, N Izumo, T Fujita, T Kohno, H Nakamuta, M Koida.   

Abstract

The anabolic effect of salmon calcitonin (SCT) on skeletal tissue was examined on glucocorticoid-induced osteopenia in female rats (12 weeks old). By the administration of methylprednisolone acetate (MPA: 0.1 mg/kg, s.c., 3 times/week) for 8 weeks, histomorphometrically detectable osteopenia with the characteristics of decreased bone formation and increased bone resorption developed in proximal tibia metaphysis. Serum osteocalcin level was also decreased by MPA treatment. Subsequent treatment with SCT (10 U/kg, s.c., 5 times/week) was found to reverse once developed osteopenia with the return of the osteocalcin level, though rats were still on MPA. Histomorphometry revealed that SCT decelerated bone resorption but augmented bone formation in this osteopenic model. After a single injection of SCT (2.5 U/kg--40 U/kg, s.c.), the serum level of parathyroid hormone (PTH) which had a potent anabolic on bone formation increased in a dose-dependent manner. These results indicate that SCT has a stimulating effect on osteoblastic bone formation and this anabolic effect may at least in part be due to its indirect effect to increase endogenous PTH secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963301     DOI: 10.1248/bpb.23.946

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

Review 1.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

2.  The effects of salmon calcitonin-induced hypocalcemia on bone metabolism in ovariectomized rats.

Authors:  Rachel A Davey; Howard A Morris
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies.

Authors:  Yu Tang; Jagdish Singh
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

4.  Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.

Authors:  Charles H Chesnut; Sharmilla Majumdar; David C Newitt; Andrew Shields; Jan Van Pelt; Ellen Laschansky; Moise Azria; Audrey Kriegman; Melvin Olson; Erik F Eriksen; Linda Mindeholm
Journal:  J Bone Miner Res       Date:  2005-04-27       Impact factor: 6.741

5.  Controlled Delivery of Salmon Calcitonin Using Thermosensitive Triblock Copolymer Depot for Treatment of Osteoporosis.

Authors:  Lindsey Lipp; Divya Sharma; Amrita Banerjee; Jagdish Singh
Journal:  ACS Omega       Date:  2019-01-14

6.  Calcitonin inhibits SDCP-induced osteoclast apoptosis and increases its efficacy in a rat model of osteoporosis.

Authors:  Yi-Jie Kuo; Fon-Yih Tsuang; Jui-Sheng Sun; Chi-Hung Lin; Chia-Hsien Chen; Jia-Ying Li; Yi-Chian Huang; Wei-Yu Chen; Chin-Bin Yeh; Jia-Fwu Shyu
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

7.  Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.

Authors:  Jun Iwamoto; Hideo Matsumoto; Tsuyoshi Tadeda; Yoshihiro Sato; James K Yeh
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.